Skip to search formSkip to main contentSkip to account menu

recurrent pancreatic cancer

Known as: Relapsed Pancreatic Cancer, Recurrent Carcinoma of Pancreas, Relapsed Cancer of Pancreas 
The reemergence of pancreatic carcinoma after a period of remission.
National Institutes of Health

Related topics

Related topics

9 relations
Epithelial CellsEpitheliumExocrine pancreasGastrointestinal system

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy
Background/Aim: The past 17 years, immune-cell therapy has been administered to 990 patients with advanced or recurrent… 
2016
2016
Neutropenia as a prognostic factor and safety of second-line therapy with S-1 for advanced or recurrent pancreatic cancer.
The aim of this retrospective study was to investigate the safety of S-1 as second-line therapy and to evaluate the association… 
2013
2013
Aggressive secondary surgery for local recurrence of pancreatic cancer
We report two cases of locally recurrent pancreatic cancer treated with repeated resection. In both cases, local recurrence was… 
Review
2010
Review
2010
What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies.
Advanced pancreatic cancer is usually treated with first-line gemcitabine (GEM) (alone or in combination). More recently, GEM has… 
2008
2008
PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen as Second-Line Therapy in Patients With Progressive or Recurrent Pancreatic Cancer After Gemcitabine-Containing Chemotherapy
Objective:The therapeutic arsenal for salvage therapy in pancreatic cancer is limited. PEFG (cisplatin, epirubicin, 5… 
2007
2007
Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study
BackgroundThis study set out to evaluate, in patients with gemcitabine-resistant pancreatic cancer, the response rate and… 
2002
2002
High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
S-1 is a newly developed oral fluoropyrimidine derivative with demonstrated activity against several tumor types. The aim of this… 
2000
2000
2. Diagnostic Utility of FDG-PET in the Clinical Management of Patients with Suspected Recurrent Pancreatic Carcinoma after Whipple Procedure.
1998
1998
Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer.
Review
1990
Review
1990
Splenic vein thrombosis.
A retrospective review of all admissions to the University of Kentucky Medical Center from 1977 to 1987 revealed six persons in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)